[go: up one dir, main page]

UY27645A1 - Mctodo para preparar dispersiones snlidas amorfas de farmacos secadas por pulverizacinn utilizando inyectores a presinn - Google Patents

Mctodo para preparar dispersiones snlidas amorfas de farmacos secadas por pulverizacinn utilizando inyectores a presinn

Info

Publication number
UY27645A1
UY27645A1 UY27645A UY27645A UY27645A1 UY 27645 A1 UY27645 A1 UY 27645A1 UY 27645 A UY27645 A UY 27645A UY 27645 A UY27645 A UY 27645A UY 27645 A1 UY27645 A1 UY 27645A1
Authority
UY
Uruguay
Prior art keywords
dispersions
snlid
presinn
mctod
amorphes
Prior art date
Application number
UY27645A
Other languages
English (en)
Inventor
Ronald A Beyerinck
Ray Roderick
Dobry Daniel
Settell Dana
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27663274&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY27645(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY27645A1 publication Critical patent/UY27645A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • A61K9/1694Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Vaporization, Distillation, Condensation, Sublimation, And Cold Traps (AREA)
  • Glanulating (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Disintegrating Or Milling (AREA)

Abstract

Dispersiones sólidas amorfas homogéneas de fármacos en polímeros mejoradores de la concentración se preparan en tamanos de partícula más grande adecuadas con minimo contenido de finos, utilizando un atomizador y condiciones de procedimiento capaces de producir gotas que tienen un diámetro medio de al menos 50 micrones y un D10 de al menos 10 micrones.
UY27645A 2002-02-01 2003-01-31 Mctodo para preparar dispersiones snlidas amorfas de farmacos secadas por pulverizacinn utilizando inyectores a presinn UY27645A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35398602P 2002-02-01 2002-02-01

Publications (1)

Publication Number Publication Date
UY27645A1 true UY27645A1 (es) 2003-09-30

Family

ID=27663274

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27645A UY27645A1 (es) 2002-02-01 2003-01-31 Mctodo para preparar dispersiones snlidas amorfas de farmacos secadas por pulverizacinn utilizando inyectores a presinn

Country Status (20)

Country Link
US (1) US7780988B2 (es)
EP (1) EP1469830A2 (es)
JP (1) JP2005523260A (es)
KR (1) KR100758045B1 (es)
CN (1) CN1787808A (es)
AR (1) AR038369A1 (es)
AU (1) AU2003239463B2 (es)
BR (1) BR0307515A (es)
CA (1) CA2474958A1 (es)
GT (1) GT200300024A (es)
MX (1) MXPA04007435A (es)
PA (1) PA8565401A1 (es)
PE (1) PE20030804A1 (es)
PL (1) PL371593A1 (es)
RS (1) RS67304A (es)
RU (1) RU2288703C2 (es)
TW (1) TW200404576A (es)
UY (1) UY27645A1 (es)
WO (1) WO2003063821A2 (es)
ZA (1) ZA200405971B (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
EP1469830A2 (en) 2002-02-01 2004-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
PL372247A1 (en) 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
ES2339682T3 (es) 2004-06-01 2010-05-24 Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag Procedimiento para la preparacion de la forma amorfa de un farmaco.
PL2489659T3 (pl) 2004-06-24 2018-06-29 Vertex Pharma Modulatory transporterów posiadających kasetę wiążącą atp
JP2007519758A (ja) 2004-12-01 2007-07-19 テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ 結晶マクロライドの生成方法
US9265731B2 (en) 2005-01-28 2016-02-23 Bend Research, Inc. Drying of drug-containing particles
JP2009502969A (ja) 2005-07-28 2009-01-29 アイエスピー インヴェストメンツ インコーポレイテッド 非晶質エファビレンツ及びその製造
CN101304970A (zh) * 2005-12-21 2008-11-12 卫材R&D管理有限公司 1,2-二氢吡啶化合物的无定形物
JP5409010B2 (ja) 2005-12-28 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド N−[2,4−ビス(1,1−ジメチルエチル)−5−ヒドロキシフェニル]−1,4−ジヒドロ−4−オキソキノリン−3−カルボキサミドの固体形態
NZ569700A (en) 2006-02-09 2011-09-30 Merck Sharp & Dohme Polymer formulations of CETP inhibitors
DK2029110T3 (da) 2006-06-06 2011-12-19 Tibotec Pharm Ltd Fremgangsmåde til fremstilling af sprøjtetørrede formuleringer med TMC125
EP2043610B1 (en) 2006-07-21 2015-07-01 Bend Research, Inc. Drying of drug-containing particles
US8613946B2 (en) 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
EP2125938A2 (en) 2007-01-26 2009-12-02 Isp Investments Inc. Formulation process method to produce spray dried products
EP2046777A2 (en) 2007-05-01 2009-04-15 Plus Chemicals B.V. Amorphous eletriptan hydrobromide and process for preparing it and other forms of eletriptan hydrobromide
US20100048912A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens, In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
ES2552087T3 (es) 2009-02-05 2015-11-25 Tokai Pharmaceuticals, Inc. Nuevos profármacos de inhibidores de CYP17 esteroidales/antiandrógenos
US8476442B2 (en) 2009-03-20 2013-07-02 Vertex Pharmaceutical Incorporated Process for making modulators of cystic fibrosis transmembrane conductance regulator
US9724664B2 (en) * 2009-03-27 2017-08-08 Bend Research, Inc. Spray-drying process
CN104997634A (zh) 2010-04-09 2015-10-28 帕西拉制药有限公司 用于配制大直径合成膜囊泡的方法
SG2014013502A (en) 2010-06-09 2014-05-29 Abbvie Inc Solid dispersions containing kinase inhibitors
WO2011163090A1 (en) 2010-06-23 2011-12-29 Metabolex, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2012031129A2 (en) 2010-09-03 2012-03-08 Bend Research, Inc. Spray-drying apparatus and methods of using the same
US9084944B2 (en) 2010-09-03 2015-07-21 Bend Research, Inc. Spray-drying apparatus and methods of using the same
WO2012040502A1 (en) * 2010-09-24 2012-03-29 Bend Research, Inc. High-temperature spray drying process and apparatus
TW201309346A (zh) 2011-01-05 2013-03-01 Hospira Inc 噴霧乾燥萬古黴素
TWI590821B (zh) * 2011-01-18 2017-07-11 輝瑞有限公司 固體分子分散液
PT106063B (pt) * 2011-12-19 2017-05-30 Inst Superior Tecnico Minociclina cristalina termorresistente produzida por recristalização com dióxido de carbono
CA2865519C (en) 2012-02-27 2018-01-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions comprising a solid dispersion of n-[2,4-bis(1,1-dimethylethyl0-5-hydroxyphenyl-1]-1,4-dihydro-4-oxoquinolone-3-carboxamide for treating cystic fibrosis
CN104321059A (zh) 2012-05-31 2015-01-28 默沙东公司 食欲素受体拮抗剂的固体剂量制剂
IN2015DN02875A (es) * 2012-09-11 2015-09-11 Medivation Prostate Therapeutics Inc
CN104144682A (zh) 2013-01-31 2014-11-12 吉利德法莫赛特有限责任公司 两个抗病毒化合物的联用制剂
CN105163735B (zh) 2013-02-01 2018-12-11 格力尔罗格克斯股份有限公司 用于治疗神经退行性疾病和其他疾病的组合物和方法
BR112015023098A2 (pt) 2013-03-14 2017-07-18 Univ Jefferson agentes de infrarregulação do receptor de andrógeno e usos dos mesmos
CN104043104B (zh) 2013-03-15 2018-07-10 浙江创新生物有限公司 含盐酸万古霉素的喷雾干粉及其工业化制备方法
CN105636594A (zh) 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
KR102239196B1 (ko) 2013-08-27 2021-04-12 길리애드 파마셋 엘엘씨 2종의 항바이러스 화합물의 조합 제제
CN103694903B (zh) * 2013-12-02 2015-07-01 南通瑞普埃尔生物工程有限公司 一种瞬干胶粘剂及其制备方法
CA2928772A1 (en) * 2013-12-05 2015-06-11 Alrise Biosystems Gmbh Process for the production of drug formulations for oral administration
US10406127B2 (en) 2014-07-25 2019-09-10 Laurent Pharmaceuticals Solid oral formulation of fenretinide
ES3009527T3 (en) * 2014-07-25 2025-03-27 Laurent Pharmaceuticals Solid oral formulation of fenretinide
KR20170063954A (ko) 2014-10-07 2017-06-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
CA2962719A1 (en) 2014-10-31 2016-05-06 Bend Research Inc. Process for forming active domains dispersed in a matrix
RS66323B1 (sr) 2014-12-05 2025-01-31 Aragon Pharmaceuticals Inc Sastavi protiv raka
EA201791251A1 (ru) 2014-12-05 2017-11-30 Арагон Фармасьютикалз, Инк. Противораковые композиции
RU2585023C1 (ru) * 2014-12-18 2016-05-27 Общество с ограниченной ответственностью "Нанолек" Способ гранулирования
WO2016198983A1 (en) 2015-06-09 2016-12-15 Bend Research Inc. Formulations to achieve rapid dissolution of drug from spray-dried dispersions in capsules
SG10202011827YA (en) 2016-04-15 2021-01-28 Novira Therapeutics Inc Combinations and methods comprising a capsid assembly inhibitor
GB201609222D0 (en) 2016-05-25 2016-07-06 F2G Ltd Pharmaceutical formulation
TW201818933A (zh) 2016-10-21 2018-06-01 美商吉利亞洛吉克斯公司 用於神經退化性及其他疾病的治療之組成物和方法
EP3765011A1 (en) 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
CN112770750A (zh) 2018-07-30 2021-05-07 中外制药株式会社 乙内酰脲衍生物的固体分散体
US20200147032A1 (en) 2018-11-14 2020-05-14 Robert K. Prud'homme Dihydromyricetin hot melt extrusion formulations and methods for forming them
US11819503B2 (en) 2019-04-23 2023-11-21 F2G Ltd Method of treating coccidioides infection
US20220370444A1 (en) * 2019-11-06 2022-11-24 Mannkind Corporation Compositions of Clofazimine, Combinations Comprising Them, Processes for Their Preparation, Uses and Methods of Treatment Comprising Them
WO2021138483A1 (en) 2019-12-30 2021-07-08 Deciphera Pharmaceuticals, Llc Amorphous kinase inhibitor formulations and methods of use thereof
LT4084779T (lt) 2019-12-30 2024-11-11 Deciphera Pharmaceuticals, Llc 1-(4-brom-5-(1-etil-7-(metilamino)-2-okso-1,2-dihidro-1,6-naftiridin-3-il) -2- fluorfenil)-3-fenilkarbamido kompozicijos
IL293866A (en) 2019-12-30 2022-08-01 Deciphera Pharmaceuticals Llc Compositions of amorphous kinase inhibitors and methods of using them
WO2022068876A1 (en) 2020-09-29 2022-04-07 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions
EP4499064A1 (en) * 2022-03-25 2025-02-05 Shenzhen Pharmacin Co., Ltd. Pharmaceutical compositions of protac compounds and uses thereof
CN120418354A (zh) 2022-12-28 2025-08-01 中外制药株式会社 含有待分散的物质的固体分散体、含有其的药物组合物及其生产方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1131242A (en) 1965-02-18 1968-10-23 Gen Foods Ltd Improvements in or relating to spray-drying apparatus
GB1329791A (en) 1971-01-19 1973-09-12 Niro Atomizer As Spray drying devices for the production of powder eg milk powder
IT1025765B (it) 1974-11-18 1978-08-30 Gastaldi Francesco Essiccatore perfezionato a spruzzo
DE2741196A1 (de) * 1977-09-13 1979-03-15 Bayer Ag Verfahren zur herstellung von perlpolymeren
US4187617A (en) * 1978-12-18 1980-02-12 Becker James J Jr Spray dryer
US4702799A (en) 1985-09-03 1987-10-27 Nestec S.A. Dryer and drying method
PH30929A (en) * 1992-09-03 1997-12-23 Janssen Pharmaceutica Nv Beads having a core coated with an antifungal and a polymer.
SI9520049A (en) * 1994-05-06 1997-12-31 Pfizer Controlled-release dosage forms of azithromycin
US5958458A (en) * 1994-06-15 1999-09-28 Dumex-Alpharma A/S Pharmaceutical multiple unit particulate formulation in the form of coated cores
DE19613691A1 (de) * 1996-04-05 1997-10-09 Boehringer Ingelheim Int Arzneimittel für die Behandlung von Tumorerkrankungen
US5858409A (en) * 1996-04-17 1999-01-12 Fmc Corporation Hydrolyzed cellulose granulations for pharmaceuticals
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
EP1027887B1 (en) 1999-02-10 2008-08-13 Pfizer Products Inc. Matrix controlled release device
EP1027886B1 (en) 1999-02-10 2008-07-09 Pfizer Products Inc. Pharmaceutical solid dispersions
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
DE60042352D1 (de) 1999-02-10 2009-07-23 Pfizer Prod Inc Osmotisches System zur Verabreichung von Wirkstoffen, die feste amorphe Dispersionen enthalten
GT200100039A (es) * 2000-03-16 2001-12-31 Pfizer Inhibidor de la glucogeno fosforilasa.
AR027656A1 (es) 2000-03-16 2003-04-09 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
PL372247A1 (en) * 2002-02-01 2005-07-11 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
EP1469830A2 (en) 2002-02-01 2004-10-27 Pfizer Products Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles

Also Published As

Publication number Publication date
KR100758045B1 (ko) 2007-09-11
JP2005523260A (ja) 2005-08-04
US20030185893A1 (en) 2003-10-02
RS67304A (sr) 2006-10-27
RU2288703C2 (ru) 2006-12-10
CA2474958A1 (en) 2003-08-07
KR20040083491A (ko) 2004-10-02
ZA200405971B (en) 2006-05-31
CN1787808A (zh) 2006-06-14
TW200404576A (en) 2004-04-01
PE20030804A1 (es) 2003-09-19
WO2003063821A3 (en) 2003-11-13
WO2003063821A2 (en) 2003-08-07
BR0307515A (pt) 2004-12-07
GT200300024A (es) 2003-09-22
US7780988B2 (en) 2010-08-24
PA8565401A1 (es) 2003-12-10
PL371593A1 (en) 2005-06-27
RU2004123639A (ru) 2005-04-20
AR038369A1 (es) 2005-01-12
AU2003239463B2 (en) 2007-10-18
MXPA04007435A (es) 2004-10-11
EP1469830A2 (en) 2004-10-27

Similar Documents

Publication Publication Date Title
UY27645A1 (es) Mctodo para preparar dispersiones snlidas amorfas de farmacos secadas por pulverizacinn utilizando inyectores a presinn
WO2001028525A3 (en) Method of producing sub-micron particles of biologically active agents
AU2002243441A1 (en) Preparation of drug particles using evaporation precipitation into aqueous solutions
EP2283822A3 (en) Spray drying processes for forming solid amorphous dispersions of drugs and polymers
WO2009095562A3 (fr) Biomateriau permettant la delivrance controlee d'actifs
WO2007116954A3 (en) Inorganic nanoparticle comprising an active substance immobilized on the surface and a polymer
MY159380A (en) Controllable filler prefloculation using a dual polymer system
BRPI0411835A (pt) processo para a preparação de partìculas esféricas
WO2007033372A3 (en) Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
SG170087A1 (en) Pharmaceutical compositions
WO2006060723A3 (en) Methods for producing block copolymer/amphiphilic particles
MXPA05007154A (es) Atomizador prepeliculizacion.
EA200600877A1 (ru) Наночастицы для доставки лекарств
MX2009005696A (es) Nanoparticulas magneticas para la aplicacion en hipertermia, preparacion de las mismas y uso en constructos que tienen una aplicacion farmacologica.
TW200740478A (en) Dispensing device
WO2007141344A3 (fr) Formulations pharmaceutiques pour la liberation prolongee de principe(s) actif(s), ainsi que leurs applications notamment therapeutiques
EP1847257A3 (en) Solid preparation comprising enteric solid dispersion
EP1847260A3 (en) Solid dispersion preparation
WO2008143239A1 (ja) 結晶性微粉化粒子
EP1886672A3 (en) Solid dosage form comprising solid dispersion and method for producing the same
GB2474402A (en) Preparation method of biodegradable micro particles containing drugs
UA105648C2 (uk) Екструдати з голчатими активними речовинами
WO2006097725A3 (en) Pharmaceutical compositions comprising microparticles for delivery into neurons
WO2007089926A3 (en) Oxcarbazepine pharmaceutical formulation and its method of preparation, wherein oxcarbazepine has a broad and multi-modal particle size distribution
WO2006099248A3 (en) Drug delivery from electroactive molecularly imprinted polymer

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150126